All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Leo Pharma's Anzupgo, first Pan-JAK inhibitor for chronic hand eczema in adults
Small molecule, autoimmune, JAK inhibitor, chronic hand eczema, topical therapy, dermatology - Read more

European Commission approves GSK's Blenrep for relapsed multiple myeloma, targeting BCMA as second-line combination treatment
Antibody, cancer, antibody-drug conjugate, multiple myeloma, BCMA target, combination therapy - Read more

European Commission approves Ipsen's Cabometyx for advanced neuroendocrine tumors following TKI's superior Phase III efficacy data
Small molecule, cancer, tyrosine kinase inhibitor, neuroendocrine tumors, pancreatic cancer, rare disease - Read more

THE GOOD
Business Development & Partnerships

Eli Lilly and Gate Bioscience partner on molecular gate technology; deal worth up to $856M plus royalties
Licensing deal, small molecule, drug discovery, milestone payments, equity investment, R&D - Read more

Galapagos regains cell therapy rights from Gilead, creates subsidiary for potential sale; owes single-digit royalties
Read more - Acquisition, cell therapy, licensing deal, divestiture, milestone payments, oncology

Novartis partners with Matchpoint Therapeutics for inflammatory disease drug discovery, $60M upfront plus $1B in potential milestones
Licensing deal, inflammatory disease, drug discovery, small molecule, milestone payments, R&D - Read more

Kling Bio partners with Sanofi to accelerate antibody discovery using proprietary B cell platform for antiviral therapies
Research collaboration, licensing deal, infectious disease, antibody, drug discovery, R&D - Read more

MilliporeSigma, Washington University sign MoU to enhance research collaboration, accelerate lab-to-clinic translation
Research collaboration, technology development, R&D, academic-industry partnership, life sciences, healthcare innovation - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

AstraZeneca's gefurulimab meets all Ph3 endpoints for myasthenia gravis, demonstrating C5 inhibitor's efficacy in autoimmune disease
Antibody, autoimmune, nanobody, myasthenia gravis, complement C5 inhibitor, subcutaneous administration - Read more

THE GOOD
Fundraises

Brandon Capital raises $290M for sixth BioCatalyst Fund supporting life sciences companies
Venture capital, life sciences, biotech investor, international focus - Read more

TCG Labs Soleil raises $400M funding to advance single-asset biotechs globally
Venture capital, biotech investment, R&D hub, clinical development, global operations - Read more

Abivax to raise $650M through public offering, developing chronic inflammatory disease therapeutics
Chronic inflammatory diseases, clinical-stage, immunotherapy, platform technology - Read more

Pharvaris raises $201.2M in public offering to develop oral bradykinin receptor antagonists for HAE
Rare disease, small molecule, clinical-stage, hereditary angioedema, autoimmune - Read more

Leads Biolabs raises $189M IPO, clinical-stage biotech funding trials and pipeline expansion
Clinical-stage, biotech, manufacturing, platform technology, preclinical - Read more

THE GOOD
Investments

German CDMO Sanner opens first US plant in North Carolina, expanding North American presence after recent acquisitions
Medical device CDMO, manufacturing expansion, operational, strategic - Read more

THE GOOD
Lawsuits

Viatris wins court ruling against Novo Nordisk in patent dispute over Wegovy generic
GLP-1 receptor agonist, obesity, diabetes, patent litigation, competitive, generic drug - Read more

THE GOOD
Mergers & Acquisitions

Bavarian Nordic confirms acquisition talks with private equity firms amid rising chikungunya outbreaks globally
Chikungunya vaccine, infectious disease, strategic, major transaction, competitive - Read more

THE GOOD
Strategic Plans

Roche considers bypassing PBMs with direct-to-patient sales in US amid drug pricing debates
Multiple sclerosis treatment, cancer, strategic, operational, pricing reform - Read more

THE BAD
Layoffs

Adicet Bio cuts 30% of staff, discontinues cancer cell therapy to prioritize autoimmune pipeline
Gamma delta CAR-T, autoimmune, oncology, strategic, operational, cost reduction - Read more

Rocket Pharmaceuticals cuts 30% of staff, prioritizes cardiovascular gene therapies amid clinical hold and regulatory challenges
Gene therapy, cardiovascular, strategic, financial, operational - Read more

Tessera Therapeutics cuts 17% of workforce in second layoff amid ongoing financial struggles
Gene therapy, strategic, cost reduction, financial challenges - Read more 

THE BAD
Market Reports

Deloitte survey: Tariffs and pricing policies create pivotal moment for life sciences companies
Healthcare policy, pricing policy, strategic, operational, financial impact - Read more

THE BAD
Strategic Plans

Galapagos explores selling its cell therapy business after backtracking on company split plan
Divestiture, cell therapy, strategic alternatives, business restructuring - Read more

Roche discontinues CT-173 PYY analog for obesity treatment in preclinical phase, citing competitive market challenges
Small molecule, metabolic, peptide therapy, obesity, GLP-1/GIP pathway, pipeline discontinuation - Read more

THE UGLY
Regulatory

FDA may ask for new safety analyses from Sarepta Therapeutics for paused DMD gene therapy Elevidys
Gene therapy, duchenne muscular dystrophy, rare disease, regulatory, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here